NICHOLAS THAMES: Open Payments
NPI 1457029951 · WESTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 45 payments from 11 companies in 2025. Trend: 2023 $1,052 · 2024 $1,836 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 12 | $237 |
| E.R. Squibb & Sons, L.L.C. | 11 | $171 |
| Axsome Therapeutics, Inc. | 3 | $100 |
| Alkermes, Inc. | 3 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| ABBVIE INC. | 3 | $76 |
| Vanda Pharmaceuticals Inc. | 3 | $50 |
| Braeburn Inc. | 3 | $48 |
| Indivior Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 1 | $25 |
Products named: REXULTI, COBENFY, Auvelity, CAPLYTA, VRAYLAR, ARISTADA, FANAPT, BRIXADI.
Industry payments across MA — which companies pay providers there.
